Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Autor: Carmelo Carlo-Stella, Carlos Grande, Valerie Belsack, Paolo Corradini, Anne-Marie Quinson, Monica Balzarotti, Francesco Zaja, Daniela Maier, Juan-Manuel Sancho, Miguel Canales, Massimo Magagnoli

Publikováno v: Investigational New Drugs
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

SummaryBackground BI 836826 is a chimeric mouse–human monoclonal antibody directed against human CD37, a transmembrane protein expressed on mature B lymphocytes. This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495164599c09f14968120e0c1071d038
https://pubmed.ncbi.nlm.nih.gov/33523334

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Autor: Danilov AV; City Of Hope National Medical Center, Duarte, CA, USA., Spurgeon SE; Knight Cancer Institute at Oregon Health & Science University, Portland, OR, USA., Siddiqi T; City Of Hope National Medical Center, Duarte, CA, USA., Quinson AM; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Maier D; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Smith D; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA., Brown JR; Dana-Farber Cancer Institute, Boston, MA, USA. Jennifer_Brown@dfci.harvard.edu.

Publikováno v: Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1099-1105. Date of Electronic Publication: 2021 Mar 08.

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Autor: Kroschinsky F; Medical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany., Middeke JM; Medical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany., Janz M; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Robert-Rössle-Straße 10, 13125, Berlin, Germany., Lenz G; Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany., Witzens-Harig M; Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany., Bouabdallah R; Department ofHematology, Institute Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France., La Rosée P; Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.; Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schweningen, Germany., Viardot A; Department of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany., Salles G; Department of Hematology, University Hospital of South Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France., Kim SJ; Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul, South Korea., Kim TM; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul, 03080, South Korea.; Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, South Korea., Ottmann O; Division of Cancer and Genetics, Department of Haematology, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Chromik J; Universitätsklinikum Frankfurt, Johann-Wolfgang-Goethe-Universität, Theodor-W.-Adorno-Platz 1, 60323, Frankfurt, Germany., Quinson AM; Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, 06877, USA., von Wangenheim U; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany., Burkard U; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany., Berk A; ClinTriCare GmbH & Co. KG, Untere Illereicher Str. 10, 89281, Altenstadt, Germany., Schmitz N; Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. Norbert.Schmitz@ukmuenster.de.

Publikováno v: Investigational new drugs [Invest New Drugs] 2021 Feb; Vol. 39 (1), pp. 285-286.